MétaCan
Menu
Back to cohort
Record W4377565617 · doi:10.1002/cpt.2956

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

2023· article· en· W4377565617 on OpenAlexaff
Michael J. Hanley, Paul M. Diderichsen, Benjamin E. Rich, Anna Largajolli, Emilie Schindler, Alexander Vorog, Karthik Venkatakrishnan, Neeraj Gupta

Bibliographic record

VenueClinical Pharmacology & Therapeutics · 2023
Typearticle
Languageen
FieldMedicine
TopicChronic Myeloid Leukemia Treatments
Canadian institutionsEspace pour la vie
Fundersnot available
KeywordsPonatinibMedicineNeutropeniaConfidence intervalInternal medicineHazard ratioOdds ratioDosingMyeloid leukemiaToxicityNilotinibImatinib

Abstract

fetched live from OpenAlex

Optimizing Ponatinib Treatment in CP‐CML (OPTIC) was a randomized, phase II dose‐optimization trial of ponatinib in chronic phase‐chronic myeloid leukemia (CP‐CML) resistant to ≥ 2 tyrosine kinase inhibitors or with T315I mutation. Patients were randomized to starting doses of 45‐, 30‐, or 15‐mg ponatinib once daily. Patients receiving 45‐ or 30‐mg reduced to 15‐mg upon achievement of ≤ 1% BCR::ABL1 IS (≥ molecular response with 2‐log reduction (MR2)). The exposure‐molecular response relationship was described using a four‐state, discrete‐time Markov model. Time‐to‐event models were used to characterize the relationship between exposure and arterial occlusive events (AOEs), grade ≥ 3 neutropenia, and thrombocytopenia. Increasing systemic exposures were associated with increasing probability of transitioning from no response to ≥ MR1, and from MR1 to ≥ MR1, with odds ratios of 1.63 (95% confidence interval (CI), 1.06–2.73) and 2.05 (95% CI, 1.53–2.89) for a 15‐mg dose increase, respectively. Ponatinib exposure was a significant predictor of AOEs (hazard ratio (HR) 2.05, 95% CI, 1.43–2.93, for a 15‐mg dose increase). In the exposure‐safety models for neutropenia and thrombocytopenia, exposure was a significant predictor of grade ≥ 3 thrombocytopenia (HR 1.31, 95% CI, 1.05–1.64, for a 15‐mg dose increase). Model‐based simulations predicted a clinically meaningful higher rate of ≥ MR2 response at 12 months for the 45‐mg starting dose (40.4%) vs. 30‐mg (34%) and 15‐mg (25.2%). The exposure–response analyses supported a ponatinib starting dose of 45 mg with reduction to 15 mg at response for patients with CP‐CML.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.728
Threshold uncertainty score0.763

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.304
GPT teacher head0.533
Teacher spread0.229 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueClinical Pharmacology & TherapeuticsSame topicChronic Myeloid Leukemia TreatmentsFrench-language works237,207